CAM, Trilegal, Khaitan, IndusLaw act on HUL’s $350 mln Minimalist deal
In the first big M&A deal in India this year, leading firm Cyril Amarchand Mangaldas has guided FMCG major Hindustan Unilever (HUL) on its acquisition of 90.5 percent stake in Jaipur-based skincare startup Minimalist for close to $350 million (29.5 billion rupees).
Uprising Science, owner of the Minimalist brand, and…
7 international, Indian firms act on Kedaara Capital’s $350 mln U.S. bet
Akin Gump Strauss Hauer & Feld, Quillon Partners, and Kelley Drye & Warren have advised Indian private equity firm Kedaara Capital on its maiden bet in the data analytics and AI solutions market, committing $350 million strategic investment to San Jose, California-based Impetus Technologies.
Saraf, TT&A facilitate Fortis’ $207 mln buyout of PE investors in Agilus Diagnostics
Saraf and Partners has acted for Fortis Healthcare in relation to the $207 million acquisition of a 31.5 percent equity stake in its subsidiary, Agilus Diagnostics, from three private equity investors.
Trilegal, CAM act on Edelweiss’ $272 mln road projects acquisition
Trilegal has advised Edelweiss-backed Epic Concesiones 2 on its $272 million acquisition of 11 road projects from Ashoka Buildcon and Ashoka Concessions, which were represented by Cyril Amarchand Mangaldas.
SAM, Latham guide Hexaware’s upcoming $1.2 bln India IPO
Indian law firm Shardul Amarchand Mangaldas & Co has been mandated to assist Hexaware Technologies, an AI-focused tech company backed by Carlyle Group, on its upcoming initial public offering (IPO) in India, which is expected to raise $1.2 billion.
AZB, Kirkland, Trilegal act on Bain Capital’s first India bet in 2025
AZB & Partners and Kirkland & Ellis have guided Bain Capital’s investment into Indian automotive component maker Dhoot Transmission Group, which was represented by Trilegal.
TT&A, SAM, Trilegal act on Quadria’s $100 mln investment in Aragen Life Sciences
Talwar Thakore & Associates advised Quadria Capital, a private equity fund focused on Asian healthcare, on its $100 million acquisition of a minority stake in Aragen Life Sciences. Shardul Amarchand Mangaldas & Co. represented Aragen in the transaction.